Catalyst
Slingshot members are tracking this event:
Vertex (VRTX) Expects Top-Line Phase 2 Data Evaluating VX-440/Tezacaftor/Kalydeco in ~40 CF Patients With F508del Mutation and One Minimal Function Mutation and ~25 CF patients With Two Copies of the F508del Mutation in H2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 18, 2017
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1033559
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Top-line Data, Phase 2, Vx-440, Tezacaftor, Kalydeco, F508del Mutation, One Minimal Function Mutation
